Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX, page-24

I think if interim results are positive for DMX200 when released in October the share price will most likely open up several cents higher on that day . However I believe the price may keep moving north as investors realise that DMx200 success means the underlying discovery platform technology that Dimerix owns is also a success, which imo is actually bigger news than DMX200 success.

Whilst DMX200 is a phase 2 trial, there is still a huge amount of risk as this trial is the first human trial for DMX200, coming straight from animal trials. Failure in the trial will be major bad news for the company going forward and may result in a share price reflecting cash backing only (think 0.001).

The other risk is that the company are unable to release info on the reduction in proteinuria in October, but release just interim safety info instead meaning we have to wait longer again for a price movement catalyst.

For me this biotech offers major rewards but still carries major risks, which probably is why we have a current market cap less than $15m. i'm not surprised people are bailing at this stage.